Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

​ Conditions: Adenocarcinoma; Prostate Cancer; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Interventions: Biological: TriAdeno vaccine; Drug: N-803

Sponsors: National Cancer Institute (NCI)

Not yet recruiting Conditions: Adenocarcinoma; Prostate Cancer; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type
Interventions: Biological: TriAdeno vaccine; Drug: N-803
Sponsors: National Cancer Institute (NCI)
Not yet recruiting